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CaSRExtracellular calcium (Ca2+o) and its receptor, the Ca2+-sensing receptor (CaSR), play an important role in pros-
tate physiology, and it has been shown that the deregulation of Ca2+ homeostasis and the overexpression of CaSR
are involved in prostate cancer (PCa). Regucalcin (RGN), a Ca2+-binding protein that plays a relevant role in
intracellular Ca2+ homeostasis, was identiﬁed as an under-expressed protein in human PCa. Moreover, RGN
was associated with suppression of cell proliferation, suggesting that the loss of RGN may favor development
and progression of PCa. This work aims to unveil the role of Ca2+o on RGN expression and viability of non-
neoplastic (PNT1A) and neoplastic (LNCaP) prostate cell lines. It was demonstrated that Ca2+o up-regulates
RGN expression in both cell lines, but important differences were found between cells for dose- and time-
responses to Ca2+o treatment. It was also shown that high [Ca
2+]o triggers different effects on cell proliferation
of neoplastic and non-neoplastic PCa cells, which seems to be related with RGN expression levels. This suggests
the involvement of RGN in the regulation of cell proliferation in response to Ca2+o treatment. Also, the effect
of Ca2+o on CaSR expression seems to be dependent of RGN expression, which is strengthened by the fact that
RGN-knockdown in PNT1A cells increases the CaSR expression, whereas transgenic rats overexpressing RGN
exhibit low levels of CaSR. Overall, our results highlighted the importance of RGN as a regulatory protein in
Ca2+-dependent signaling pathways and its deregulation of RGN expression by Ca2+o may contribute for
onset and progression of PCa.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Prostate cancer (PCa) is the most common male cancer concerning
the number of new cases diagnosed, and represents one of the major
causes of cancer death in men worldwide [1,2]. Apart from androgens,
it iswell known the role of calcium (Ca2+) in the physiology of prostate,
and the deregulation of Ca2+ homeostasis has been intimately associat-
ed with development and progression of PCa [3]. Over recent years,
a growing body of evidence has indicated that extracellular Ca2+
(Ca2+o), mainly through the activity of extracellular calcium-sensing
receptor (CaSR), regulates cell proliferation, differentiation, and apopto-
sis [4]. In addition, several studies have pointed out that the activation of
CaSR is associatedwith the onset of PCametastasis [5,6], which stronglycer; RGN, Regucalcin; HCC,
concentration; CaSR, calcium-
ats overexpressing RGN; qPCR,
.
Saúde, Av. Infante D. Henrique,
, cmaia@fcsaude.ubi.pthighlights the importance of Ca2+ signaling and homeostasis in the
pathophysiology of prostate gland.
Regucalcin (RGN) is a Ca2+-binding protein that plays an important
role in maintaining intracellular Ca2+ homeostasis by regulating the
activity of Ca2+ pumps in plasma membrane and endoplasmic reticu-
lum, and the uptake of Ca2+ bymitochondria [7,8]. Also, it was reported
that overexpression of RGN suppresses the expression of CaSR [9].
Noteworthy RGNwas described as an underexpressed protein in differ-
ent types of human cancer cell lines and tissues, namely, in the hepato-
cellular carcinoma (HCC), and in breast and prostate cancers [10–13].
Our previous work also demonstrated that the loss of RGN expression
in human PCa cases is negatively correlated with the cellular differenti-
ation of adenocarcinoma [12]. Moreover, it was recently shown that
RGN decreases cell proliferation in rat prostate through regulating the
expression of cell cycle regulators [14], which supports that reduced
levels of RGN may be implicated in development and progression of
prostate tumors. Regarding the regulation of RGN expression, it was
demonstrated that DHT down-regulates RGN levels in rat prostate and
in human androgen-sensitive LNCaP PCa cells. However, the myriad of
factors that maintain RGN expression levels in human prostate cells is
not entirely known. Considering the importance of Ca2+ in prostate
pathophysiology, and the role of RGN in Ca2+ homeostasis and cell
proliferation, this work aims to determine the effect of [Ca2+]o on the
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and neoplastic prostate cells. In addition, the expression of CaSR in
human non-neoplastic and neoplastic prostate cells, as well as, in the
prostate of transgenic animals overexpressing RGN (Tg-RGN), was
also investigated.
2. Materials and methods
2.1. Cell lines and experimental layout
The humanPCa cell lines, LNCaP and PC3, and the immortalized non-
neoplastic human prostate epithelial cell line, PNT1A, were purchased
from the European Collection of Cell Cultures (ECACC, Salisbury, UK).
All prostate cell lines were cultured in DMEM 21068 (Gibco, Paisley,
UK), supplemented with 1.8 mM CaCl2 (VWR, Leuven, Belgium), 10%
FBS (Biochrom, Berlin, Germany) and 1% penicillin/streptomycin
(Invitrogen) at 37 °C in an incubator equilibrated with 5% CO2.
Cells were grown up to 60% conﬂuence, and 24 h before stimulation,
culture medium was changed to a Ca2+ free medium, DMEM 21068
(Gibco) containing 10% FBS (Biochrom) and 1% penicillin/streptomycin
(Invitrogen). Cultured cells were maintained for additional 24 h and
then exposed to different concentrations of CaCl2 (0, 1, 1.8, 3, 5 and
10 mM) for 0, 1.5, 3, 6, 12, 24, 48 and/or 72 h. During the time-course
experiment for different Ca2+ stimuli, cells were harvested and stored
at −80 °C until RNA and protein extraction, or cell viability assays
were performed.
For RGN gene knockdown in PNT1A and LNCaP cells, several trans-
fection conditions were previously optimized. Cells were seeded in six
plate multiwells and at 40% conﬂuence were transfected with 10 nM
of a small interfering RNA (siRNA) targeting the RGN (s17374)
(Ambion, USA) and 5 μL of lipofectamine 2000 (Invitrogen, USA) for
24 h in Opti-MEM medium (Invitrogen), following manufacturer's
instructions. As control for RGN speciﬁc targeting, a Scramble siRNA se-
quence (AM4635) (Ambion, USA) was used. The mediumwas replaced
to DMEM 21068 (Gibco) supplemented with 1.8 mMCaCl2 (VWR), 10%
FBS (Biochrom) and 1% penicillin/streptomycin (Invitrogen), and the
RGN gene knockdown was conﬁrmed by Western blot after 36 h of
incubation with the siRNA.
2.2. Animals
Wild-type male rats (Rattus norvegicus) of Sprague Dawley strain
were obtained from Charles River (Barcelona, Spain). Sprague Dawley
transgenic rats overexpressing RGN (Tg-RGN) were originally generat-
ed by Yamaguchi M by oocyte transgene pronuclear injection [15] and
were purchased from Japan SLC (Hamamatsu, Japan) that commercial-
izes the strain. All rats were euthanized under anesthesia (Clorketam
1000, Vetoquinol, Lure, France) and whole prostates were removed
and frozen in liquid nitrogen for protein extraction.
2.3. Total RNA extraction and cDNA synthesis
Total RNA from human prostate cell lines was extracted using the
TRI reagent (Sigma-Aldrich, Saint Louis, Missouri, USA) according to
the manufacturer's instructions. The quantity and quality of extract-
ed RNA were assessed by spectrophotometry (Pharmacia Biotech,
Ultrospec 3000, Cambridge, England) and agarose gel electrophoresis,
respectively. For cDNA synthesis, 1 μg of total RNA was denatured for
5 min at 70 °C together with 250 ng of random hexamer primers
(Invitrogen), and reverse transcription was carried out at 37 °C for
60 min in a 20 μl reaction containing reverse transcriptase buffer, 1 μl
of dNTP Mix (10 mM each; GE Healthcare, Buckinghamshire, UK) and
200 U of M-MLV Reverse Transcriptase (Promega, Madison, WI, USA).
The reaction was stopped at 75 °C for 15 min and synthesized cDNA
was stored at−20 °C until further use.2.4. Quantitative Real-Time PCR (qPCR)
Quantitative Real-Time (qPCR) was carried out to evaluate the
mRNA expression of RGN in human prostate cell lines (PNT1A and
LNCaP), in response to Ca2+ stimuli. Speciﬁc primers for human RGN
(Sense: 5′-GCAAGTACAGCGAGTGACC-3′; antisense: 5′-TTCCCATCAT
TGAAGCGATTG-3′) ampliﬁed a fragment of 177 bp. Human beta-2-
microglobulin (β2M) (Sense: 5′-ATGAGTATGCCTGCCGTGTG-3′; anti-
sense: 5′-CAAACCTCCATGATGCTGCTTAC-3′) and GAPDH (sense: 5′-
CGCCAGCCGAGCCACATC-3′; antisense: 5′-CGCCCAATACGACCAAAT
CCG-3′) primers were used as internal controls to normalize RGN
expression. qPCR reactions were carried out in IQ5 system (Bio-Rad,
Hercules, USA) and the efﬁciency of ampliﬁcations was determined for
all primer sets using serial dilutions of cDNA (1, 1:10 and 1:100). PCR
conditions and reagents concentrations were previously optimized
and the speciﬁcity of the amplicons was determined by melting curves
analysis. For qPCR reactions, 1 μl of synthesized cDNA was used in a
20 μl reaction containing 10 μl Maxima™ SYBR Green/Fluorescein
qPCR Master Mix (Fermentas, Burlington, Canada) and sense and anti-
sense primers (200 nM for RGN and 300 nM for β2M and GAPDH).
Reaction conditions comprised 5 min denaturation at 95 °C, followed
by 35 cycles of 95 °C for 10 s, a speciﬁc annealing temperature of 60 °C
for 30 s and 72 °C for 10 s. Samples were run in triplicate in each PCR
assay. Normalized expression values were calculated following the
mathematical model proposed by Pfafﬂ using the formula: 2−ΔΔCt [16].
2.5. Western blot
Total proteins were extracted from human prostate cell lines
(PNT1A and LNCaP) and rat prostate using RIPA buffer (150 mM NaCl,
1% Nonidet-P40 substitute, 0.5% Na-deoxycholate, 0.1% SDS, 50 mM
Tris pH 8 and 1 mM EDTA) supplemented with protease inhibitors
cocktail. Protein concentration was determined by the Bradford assay
(Bio-Rad) and approximately 60 μg of cell and tissue protein extracts
was resolved by SDS-PAGE on 12% gels and electrotransferred to
a PVDF membrane (GE Healthcare). Membranes were incubated
overnight at 4 °C with mouse anti-RGN (1:1000, ab81721, Abcam,
Cambridge, United Kingdom) or mouse anti-calcium sensing receptor
clone HL1499 (1:1000, C0493, Sigma-Aldrich) primary antibodies. A
mouse anti-β-actin antibody (1:5000, A5441, Sigma-Aldrich) was
used for normalization of protein expression.Membraneswere incubat-
ed for 1 h with goat anti-mouse IgG + IgM-AP (1:5000, NIF1316; GE
Healthcare) used as secondary antibody. Finally, membraneswere incu-
bated with ECF substrate (GE Healthcare) for 3 min, and visualized on
theMolecular Imager FX Pro plusMultiImager (Bio-Rad). Band densities
were obtained according to standard methods using the Quantity
One Software (Bio-Rad) and normalized by division with the respective
β-actin band density.
2.6. Immunoﬂuorescence microscopy
PNT1A and LNCaP cells were ﬁxed with 4% paraformaldehyde for
10 min and permeabilized with 0.1% Triton X-100 during 5 min. A
blocking step was performed by incubating cells with 20% FBS in phos-
phate buffer saline (PBS) containing 0.1% tween®-20 (PBST) for 1 h at
room temperature, and then, cells were incubated with anti-RGN anti-
body (1:50, ab81721, Abcam) for 1 h at room temperature. The Alexa
ﬂuor 488 and 546 conjugated goat anti-mouse IgG (Invitrogen) were
used as secondary antibodies. The speciﬁcity of the staining was
accessed by omission of the primary antibody. Cell nuclei were stained
with Hoechst 33342 (10 mg/ml, Invitrogen) for 10 min. Lamellae were
washed and mounted onto microscope slides with Dako ﬂuorescent
mounting medium (Dako, Glostrup, Denmark). Images were acquired
using a Zeiss LSM 710 laser scanning confocal microscope (Carl Zeiss,
Göttingen, Germany).
Fig. 1. RGNmRNA (A) andprotein (B) expression in non-neoplastic (PNT1A) andneoplastic
(LNCaP and PC3) human prostate cell lines. mRNA expression was determined by qPCR
after normalization with β2M and GAPDH housekeeping genes. Protein expression was
analyzed by Western Blot and normalized with β-actin. All results are expressed as fold-
variation relatively to PNT1A. Error bars indicate mean ± SEM, n = 5. * P b 0.05;
***P b 0.001. Representative immunoblots are shown in bottom panel.
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PNT1A and LNCaP cells were seeded into 96-well plates at a density
of 1.5× 103 cell perwell in 100 μl of cellmediumculture, and exposed to
0, 1, 1.8, 3, 5 and 10 mM of CaCl2 for 0, 6, 12, 24, 48 and 72 h, as
described above. Cell viability was determined by a colorimetric
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-
sulfophenyl)-2 M) tetrazolium (MTS) assay using CellTiter 96®
AQueous One Solution Cell Proliferation Assay (Promega, Madison,
WI, USA). The conversion of MTS compound to the colored formazan
product was detected by measurement of absorbance at 490 nm in a
Microplate Reader (Biochrom, Anthos 2020). The relative number of
viable cells in each experimental conditionwas calculated by normaliz-
ing the absorbance to that of the corresponding control. All experiments
were repeated at least three times, and each experimentwas carried out
in hexaplicated.
2.8. Statistical analysis
The statistical signiﬁcance of differences in mRNA and protein
expression and cell viability among experimental groups was assessed
by Student's t-test or by ANOVA followed by the Bonferroni test. Signif-
icant differences were considered when P b 0.05 (*,#), P b 0.01 (**, ##)
or P b 0.001 (***, ###). All experimental data are shown asmean±SEM.
The Graphpad Prism 5.0 program (GraphPad Software, San Diego, CA,
USA) was used for this analysis.
3. Results
3.1. Regucalcin expression is signiﬁcantly diminished in human prostate
cancer cell lines
The mRNA and protein expression of RGN in neoplastic (LNCaP and
PC3) and non-neoplastic (PNT1A) human prostate cells, was compared
by means of qPCR and Western blot analysis (Fig. 1). The expression of
RGNmRNA (Fig. 1A) and protein (Fig. 1B)was signiﬁcantly decreased in
both PCa cell lines comparatively with PNT1A cells (LNCaP cells, 0.24-
and 0.79-fold variation for mRNA and protein, respectively; PC3 cells,
0.46- and 0.83-fold variation for mRNA and protein, respectively).
3.2. Extracellular calcium exerts a biphasic effect on regucalcin expression
Considering the role of RGN in Ca2+ homeostasis, we have hypothe-
sized that Ca2+o regulates RGNgene expression, and that this effectmay
differ between neoplastic and non-neoplastic prostate cells. Taking into
account that RGN is an androgen-responsive gene [12,14,17], we have
used the androgen-sensitive LNCaP and the non-neoplastic PNT1A cell
lines to evaluate the responsiveness of RGN expression to Ca2+o.
qPCR results demonstrated that Ca2+o exerts a biphasic effect on
RGNmRNA expression in both cell lines. In PNT1A cells, it was observed
an up-regulation of RGN after 1.5 h of stimulation with 1, 1.8 and 3mM
Ca2+o (respectively, 1.48-, 1.6- and 1.71-fold variation relatively to
PNT1A untreated cells; Fig. 2A).
Regarding LNCaP cells, a signiﬁcant up-regulation was only visible
after 3 h of treatment with 1.8 mM Ca2+o (1.7-fold variation relatively
to LNCaP untreated cells; Fig. 2B). Thereafter, the levels of RGN were
reduced along the experimental time-course, and a signiﬁcant down-
regulation of RGN mRNA was observed in both cell lines after 12 h of
stimulation with [Ca2+]o of 1, 1.8, 3, 5 and 10 mM (respectively, 0.40-,
0.36-, 0.39-, 0.71- and 0.53-fold variation in PNT1A cells relatively
to control untreated group; and 0.68-, 0.70-, 0.64-, 0.70- and 0.59-fold
variation in LNCaP cells relatively to control untreated group).
Considering 1.8 mM as the physiological [Ca2+]o, the effects of
low (1 mM) and high (5 and 10 mM) doses of Ca2+o were also
compared to 1.8 mMCa2+o. In PNT1A cells, the results showed a dimin-
ished expression of RGN after 1.5 h of stimulation with 5 and 10 mM(respectively, 43% and 48% of reduction in PNT1A cells relatively to
1.8 mM Ca2+o). However, a signiﬁcant increase in RGN levels was
observed at 3 and 12 h after treatment with 5 mM Ca2+o (respectively,
36 and 49% of reduction in PNT1A cells relatively to 1.8mM Ca2+o). The
treatmentwith 10mMCa2+o decreased the levels of RGN inPNT1A cells
at 3 h (30%), but increased at 12 h (32%) relatively to 1.8 mM Ca2+o
(Fig. 2A).
In LNCaP cells, a signiﬁcant reduction in RGN levels was observed
with 3 mM Ca2+o at 3 and 6 h (respectively, 41 and 51% reduction rela-
tively to 1.8 mMCa2+o). Also, a signiﬁcant reduction in RGN expression
was observed after treatment of LNCaP cells with 5 and 10 mM Ca2+o
(respectively, 39 and 50% at 1.5 h; 49 and 69% at 3 h; and 62 and 50%
at 6 h relatively to 1.8 mM Ca2+o). At 12 h of stimulation, no signiﬁcant
differences were perceived for the effect of 1, 3, 5 and 10 mM Ca2+o
comparatively with the 1.8 mM Ca2+o. These results suggest a time
and dose-dependent effect of Ca2+o on RGN expression in human pros-
tate cells. Subsequently, the RGN protein expression in response to
Ca2+-stimulation was investigated by means of Western blot and
immunoﬂuorescence analysis. Ca2+o treatment for 1.5 h and 3 h was
the experimental time-points selected for protein analysis, respectively,
in PNT1A and LNCaP cells, as it corresponded to the increased ex-
pression of RGN mRNA relatively to untreated control group. Dose-
response analysis for different [Ca2+]o demonstrated that PNT1A cells
treatedwith 1, 1.8 and 3mMCa2+o for 1.5 h show increased expression
of RGN protein (respectively, 2.11-, 1.96- and 1.59-fold variation rela-
tively to PNT1A untreated cells; Fig. 2C), whereas no changes were
observed in the experimental group treated with high [Ca2+]o.
In accordance with the results of mRNA expression, a signiﬁcant
reduction on RGN protein levels after treatment with 5 and 10 mM
Fig. 2.Effect of extracellular Ca2+ (Ca2+o) on RGNexpression in PNT1Aand LNCaP cells.mRNA expression of RGN(A, B)wasdetermined by qPCRafter normalizationwithβ2MandGAPDH
housekeeping genes. RGN protein expression (C, D) was analyzed byWestern blot and normalizedwith β-actin. All results are expressed as fold-variation relatively to the control untreated
group (0 mM Ca2+o). Error bars indicate mean ± SEM, n = 6. ⁎, # P b 0.05; ⁎⁎, ## P b 0.01; ⁎⁎⁎, ### P b 0.001 relatively to untreated cells or 1.8 mM Ca2+o, respectively. Representative
immunoblots are shown in bottom panel.
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Ca2+o, Fig. 2C) was also observed.
Also, LNCaP cells treated with 1 and 1.8 mM of Ca2+o for 3 h,
displayed increased RGN protein expression (respectively, 1.26- and
1.45-fold variation relatively to LNCaP untreated cells; Fig. 2D), whereas
the expression of RGN is diminished in cells stimulated with 10 mM of
Ca2+o (0.62-fold variation relatively to LNCaP untreated cells; Fig. 2D).
Comparing the effect of high doses (3, 5 and 10 mM Ca2+o) with the
physiological dose, a signiﬁcantly decreased protein expression of RGN
was observed in LNCaP cells (respectively, 21, 41 and 57% of reduction
relatively to 1.8 mM Ca2+o, Fig. 2D).
Comparing the effect of Ca2+o between non-neoplastic and neoplas-
tic human prostate cell lines, it is possible to infer that Ca2+o-induced
up-regulation of RGN protein expression is more pronounced in
PNT1A cells than in LNCaP cells. Immunoﬂuorescence results (Fig. 3)
also showed enhanced staining of RGN in the cytoplasm of PNT1A and
LNCaP cells treated with 1.8 mM Ca2+o for 1.5 h and 3 h, respectively.
This enhancement also was evident in the nucleus of PNT1A cells.3.3. Cell viability of prostate cells is dependent on extracellular calcium
concentration
Considering that Ca2+o can affect cell growth rate, we evaluated
the effect of several [Ca2+]o on the viability of PNT1A (Fig. 4A) and
LNCaP (Fig. 4B) cells for 72 h by means of MTS assay. PNT1A cells
stimulated with 3, 5 and 10 mM of Ca2+o displayed diminished cell
viability comparatively with the control untreated group (**P b 0.01
or ***P b 0.001) throughout the experimental time-course. For 48 h
of stimulation with 1.8 mM Ca2+o, the percentage of viable PNT1A
cells was enhanced when compared to control group, increasing even
further thereafter. On the other hand, the viability of LNCaP cells after
48 h of treatment was stimulated with 1.8 mM or higher [Ca2+]o
relatively to untreated cells or cells treated with 1 mM of Ca2+o
(***P b 0.001).
Comparing the effect of high and low [Ca2+o] on cell viability, it was
observed a diminished viability in both cell lines when compared to the
physiological dose of Ca2+o (1.8 mM, Fig. 4).
Fig. 3. Representative confocal microscopy images showing the expression and subcellular localization of RGN in PNT1A (red) and LNCaP (green) cells treated with 0, 1.8 and 10 mM of
Ca2+o for 1.5 h and 3 h, respectively. Nuclei are stained with Hoechst 33342 (blue). Negative controls (NC) for RGNwere obtained by omission of the primary antibody. Co-localization of
RGN and nucleus is shown by the inserted arrows.
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receptor
Even small changes in [Ca2+]o are sensed by the G-protein coupled
receptor CaSR, which upon ligand binding translates this information
to intracellular signaling pathways [4]. So, we ﬁrst analyzed the expres-
sion of CaSR protein in PNT1A and LNCaP cells bymeans ofWestern blot
analysis. The obtained results demonstrated that LNCaP cells express
higher levels of CaSR relatively to the non-neoplastic PNT1A cells
(2.08-fold variation; Fig. 5A). Considering the effect of [Ca2+]o on the
expression of RGN and viability of PNT1A and LNCaP cells, together
with other reports indicating that up-regulation of RGN expression
may inﬂuence the expression of CaSR [9], we decided to evaluate the
effect of Ca2+o on the expression of CaSR in these human prostate
cell lines. The protein levels of CaSR in response to 1.8 mM Ca2+o in
PNT1A and LNCaP cells were determined by Western blot analysis.
The results obtained showed that CaSR protein expression signiﬁcantly
decreased in PNT1A cells treated with 1.8 mM of Ca2+o for 3 h and 6 h
when compared with the control group (0.7-fold variation relativelyFig. 4. Effect of extracellular Ca2+ on the viability of PNT1A and LNCaP cells determined by the
⁎⁎, ##P b 0.01 and ⁎⁎⁎, ###P b 0.001 relatively to untreated cells or 1.8 mM Ca2+o, respectivelyto PNT1A untreated cells; Fig. 5B). In what concerns LNCaP cells, no sig-
niﬁcant differences were observed on CaSR protein expression between
the experimental groups (Fig. 5C).
3.5. RGN down-regulates the expression of CaSR
In order to investigate the role of RGN on the regulation of CaSR, we
analyzed the expression of CaSR protein in PNT1A and LNCaP cells after
RGN knockdown. In addition, the expression of CaSR was compared
between the prostate of Tg-RGN animals and their wild-type counter-
parts. As expected, the levels of RGN in PNT1A and LNCaP cells
decreased after transfection with siRNA targeting RGN (respectively,
0.27 and 0.56-fold variation relatively to control cells, *P b 0.05;
Fig. 5D and E).Western blot results demonstrated that RGN knockdown
induces the expression of CaSR in PNT1A cells (1.21-fold variation rela-
tively to control cells, *P b 0.05; Fig. 5D), but no differences were
observed in LNCaP cells (Fig. 5E). Accordingly, transgenic overexpres-
sion of RGN down-regulates CaSR levels. The prostates of Tg-RGN rats
displayed diminished expression of CaSR protein relatively to theMTS assay. Error bars indicate mean ± SEM, n = 6. #P b 0.05 relatively to 1.8 mM Ca2+o;
.
Fig. 5. CaSR protein expression in human prostate cell lines (PNT1A and LNCaP) (A), and effect of 1.8 mMof extracellular Ca2+ on CaSR expression in PNT1A (B) and LNCaP (C) cells. RGN
gene knockdown and its effect on CaSR expression in PNT1A (D) and LNCaP (E) cells, and CaSR protein expression in the prostate of transgenic rat overexpressing RGN (Tg RGN)
comparatively with their wild type counterparts (F). Results are expressed as fold-variation relatively to the control groups. Protein expression was analyzed by Western blot and
normalized with β-actin. Representative immunoblots are shown. Error bars indicate mean ± SEM, n = 6. * P b 0.05; **P b 0.01; ***P b 0.001.
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these results indicate that RGN may control the expression levels of
CaSR in prostate cells.
4. Discussion
The onset and progression of PCa are intimately dependent on the
regulation of different signaling pathways controlled by androgens
and Ca2+ [3,18], which also includes the inﬂuence of Ca2+o through
the activity of CaSR. Although themechanisms underlying Ca2+ actions
in PCa are not completely elucidated, several studies have linked the
CaSR, and also the RGN protein, with prostate carcinogenesis.
It has been demonstrated that loss of RGN expression is associated
with progression of PCa [12] and that RGN attenuates proliferation of
prostate cells [14], suggesting that this Ca2+-binding protein may
have a protective role against the development of prostate tumors. In
this way, it is absolutely crucial to characterize the factors that control
RGN expression in prostate cells under normal and pathological condi-
tions. This work ﬁrst intended to ascertain the effect of Ca2+o on the
expression of RGN in neoplastic and non-neoplastic prostate cell lines.
As a starting point, the expression of RGN was analyzed in non-
neoplastic, PNT1A cells, and in androgen-responsive and androgen
non-responsive neoplastic cell lines, LNCaP and PC3, respectively.
LNCaP and PC3 cells displayed lower levels of RGN in comparison with
PNT1A cells, which is in agreement with other studies demonstrating
that RGN is underexpressed in human PCa cases [12]. Also, the reduced
levels of RGN in LNCaP cells are concordant with the previously de-
scribed down-regulatory effect of DHT on RGN expression in PCa cells
[12]. Nevertheless, other factors must be involved in the diminution of
RGN levels in PCa, since androgen-insensitive PC3 cells also displayed
reduced expression of RGN. Taking into account the present ﬁndings,
and our previous data indicating RGN as an androgen-responsive gene
[14,19,20], PNT1A and LNCaP cells were selected to investigate therole of Ca2+o in regulating the expression of RGN. The results obtained
demonstrated that Ca2+o induced time- and dose-dependent effects
on the expression of RGN. A physiological [Ca2+]o (1.8 mM) promptly
increased RGN mRNA and protein levels in PNT1A and LNCaP cells
for 1.5 h and 3 h of stimulus, respectively. However, when cells were
stimulated with higher [Ca2+]o (3 mM and 5 mM) the effect on up-
regulation of RGN expression was only observed in PNT1A cells, which
indicates that the regulation of RGN expression by Ca2+o differs
between non-neoplastic and neoplastic prostate cells. Others have de-
scribed the regulation of RGN by Ca2+o in rat and mice liver, with RGN
mRNA being markedly increased at 30 and 60 min after intraperitoneal
administration of CaCl2 [21,22], or between 30 and 180 min following a
single oral administration of CaCl2 solution [23]. The stimulatory effect
on RGN concentration was also described in the rat kidney cortex
60 to 120 min after of a single intraperitoneal administration of a
CaCl2 solution [24].
Interestingly, when PNT1A and LNCaP cells were treated for longer
periods (6 to 12 h), the levels of RGN mRNA and protein were down-
regulated relatively to untreated cells, suggesting that RGN may trigger
a negative feedback in order to decrease its cell levels and avoid anover-
stimulation by RGN. Considering that RGN has been involved in the
regulation of Ca2+-dependent intracellular signaling pathways [25],
and the importance of Ca2+o in prostate cells, it is liable to speculate
that the up-regulation of RGN expression in response to Ca2+o may
play an important role in prostate physiology. In addition, it also should
be highlighted the Ca2+o effects relatively to 1.8 mM Ca2+o, which is
considered the physiological [Ca2+]o. The present results showed that
extreme concentrations of Ca2+o, namely high levels, decrease the ex-
pression of RGN in both cell lines relatively to physiological [Ca2+]o.
Therefore, it is liable to speculate that changes in serum [Ca2+]o may
decrease the expression of RGN, and consequently, favor the prolif-
eration of prostate cells and tumor development and progression.
Indeed, although there are contradictory results, some epidemiologic
2627C.V. Vaz et al. / Biochimica et Biophysica Acta 1853 (2015) 2621–2628studies have found that higher levels of Ca2+o are associated with PCa
risk [26,27].
Our research grouppreviously demonstrated that prostates fromTg-
RGN rats present reduced cell proliferation underpinned by decreased
expression of the oncogene H-Ras and increased levels of the cell cycle
inhibitor p21 [14]. Although it has not been demonstrated the role of
RGN as a transcription regulator, the immunoﬂuorescence results ob-
tained herein showed increased accumulation of RGN in the nucleus,
namely in PNT1A cells, suggesting that RGN may play a role in regulat-
ing thenuclear function. These results are corroborated by other studies,
which also demonstrated the presence of RGN in the nucleus of several
human cell types including prostate cells, and suggested that it may
regulate gene expression [9,12,28].
Considering the available reports describing the effect of Ca2+o on
cell proliferation [4], the present study also evaluated how distinct
[Ca2+]o inﬂuence the proliferation of PNT1A and LNCaP cells. Remark-
ably, the stimulation with high [Ca2+]o (3, 5 and 10 mM) triggered
different responses in non-neoplastic and neoplastic cell lines. In
PNT1A cells, high [Ca2+]o decreased cell viability comparatively with
the control but the opposite effect was observed in LNCaP cells. Note-
worthy, the perceived effects on cell proliferation followed concomitant
responses on the expression of RGN, since it was always visible, except
with 10 mM Ca2+o, an up-regulation of RGN expression in PNT1A cells,
whereas in LNCaP cells this effect was only visible with physiological
dose. Our results also showed that both cell lines presented decreased
proliferation when treated with low or high concentrations of Ca2+o
relatively to 1.8 mM Ca2+o. However, the diminished proliferation in
response to high doses of Ca2+o is less evident in LNCaP cells, suggesting
that cancer cells may become more sensitive to proliferation than nor-
mal cells in the presence of high concentrations of Ca2+o. Altogether,
and even considering many other mechanisms involved in the action
of Ca2+o, our results suggest that the up-regulation of RGN in response
to physiological [Ca2+]o may play an important role in protecting cells
from proliferation. These observations are supported by previews
ﬁndings demonstrating that overexpression of RGN suppresses cell
proliferation in NRK52E and hepatoma H4-II-E cells, and in rat prostate
by decreasing the expression of cell cycle regulators [14,29–32]. Never-
theless, other studies are required to fully clarify the impact of RGN
levels on the regulation of cell proliferation in neoplastic and non-
neoplastic prostate cell lines.
It is well described that one of the mechanisms of Ca2+o action is
through its cognate receptor, the CaSR [4]. It has been reported that
Ca2+ and the CaSR are important players in tumorigenesis, and in PCa,
the CaSR is even over-expressed [6]. Therefore, we compared the ex-
pression of CaSR between PNT1A and LNCaP cells. Our results showed
that LNCaP cells display higher levels of CaSR than PNT1A cells, which
is in accordance with previous ﬁndings describing a positive correlation
between activation of CaSR and development of PCa [6]. We investigat-
ed the putative role of RGN controlling CaSR expression in PNT1A
and LNCaP cells after treatment with 1.8 mM Ca2+o. Interestingly, a
decreased expression of CaSR protein was only observed in PNT1A
cells after 3 h of treatment, but no signiﬁcant changes were found in
LNCaP cells up to 12 h of treatment. Considering the high levels of
RGN at 1.5 h after treatment with physiological [Ca2+]o in PNT1A
cells, these results suggest that the down-regulation of CaSR may
occur due to the higher levels of RGN induced by this [Ca2+]o. Inversely,
the reduced levels of RGN in LNCaP cells associated with their lower
capacity to increase RGN expression in response to [Ca2+]o may explain
the absence of effects on the expression of CaSR in LNCaP cells treated
with 1.8 mM Ca2+o. In an effort to support the hypothesis that RGN
may be involved in the regulation of CaSR in prostate cells, we analyzed
the expression of CaSR protein in PNT1A and LNCaP cells after RGN
knockdown, and, also, in the prostate of Tg-RGN animals. The RGN
gene knockdown induced the CaSR expression in PNT1A but not
in LNCaP cells, suggesting that the normal role of RGN in down-
regulating CaSRmay be lost in cancer cells. The role of RGN in regulationof CaSR levels in normal prostate is strengthened by the fact that Tg-
RGN animals displayed lower levels of CaSR in comparison with their
wild type counterparts. These results are in accordance with the previ-
ously described in kidney cells, where RGN had a suppressive effect
on the expression of proteins involved in intracellular Ca2+-signaling
pathways, including the CaSR [9]. Taken together, our results suggest
that RGNmay not only have an important role in the control of cell pro-
liferation but also in desensitizing the signaling pathways triggered by
CaSR. This is strongly supported by the histopathological ﬁndings in
human PCa samples, which showed over-expression of CaSR and loss
of RGN [12,33].
In sum, it was ﬁrst demonstrated that RGN expression is regulated
by Ca2+o, in non-neoplastic and neoplastic PCa cells. However, impor-
tant differences on dose- and time-responses to [Ca2+]o were observed
between PNT1A and LNCaP cells, with PNT1A cells displaying more
pronounced effects in the up-regulation of RGN by Ca2+o. In addition,
a physiological [Ca2+]o down-regulated CaSR expression in non-
neoplastic cells, an effect not observed in PCa cells, which plausibly
could be linked to the differential response in RGN expression upon
treatment Ca2+o. These results strengthen the role of RGN in the
modulation of intracellular Ca2+-signaling pathways, and indicate that
abnormalities in the [Ca2+]o may deregulate RGN expression levels
contributing for PCa onset and progression.
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